SEC Info - Exelixis, Inc. - IPO: ‘POS EX’ on 4/11/00

SEC Info℠

Home

Help

Please Sign In

Exelixis, Inc. – IPO: ‘POS EX’ on 4/11/00

On: Tuesday, 4/11/00 · Effective: 4/11/00 · Accession #: 1012870-0-2020 · File #: 333-96335

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 4/11/00  Exelixis, Inc.                    POS EX      4/11/00    2:321K                                   Donnelley R R & S… 13/FA

Initial Public Offering (IPO): Post-Effective Amendment to Add Exhibits
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: POS EX      Post Effective Amendment #1                           10     50K 
 2: EX-10.13    Research Collaboration Agreement                      92    391K

POS EX — Post Effective Amendment #1
Document Table of Contents

Page	(sequential)	\|	(alphabetic)	Top
			Alternative Formats (Word, et al.) Exhibits and Financial Statement Schedules Indemnification of Directors and Officers Other Expenses of Issuance and Distribution Recent Sales of Unregistered Securities Undertakings
1	1st Page - Filing Submission
3	Item 13. Other Expenses of Issuance and Distribution
"	Item 14. Indemnification of Directors and Officers
4	Item 15. Recent Sales of Unregistered Securities
"	Item 16. (A). Exhibits and Financial Statement Schedules
6	Item 17. Undertakings

POS EX 1st Page of 10 TOC ↑Top Previous Next ↓Bottom Just 1st
 
As filed with the Securities and Exchange Commission on April 10, 2000      
                                                      Registration No. 333-96335
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

----------------

POST-EFFECTIVE      

AMENDMENT NO. 1 TO FORM S-1     
REGISTRATION STATEMENT
Under THE SECURITIES ACT OF 1933

----------------

Exelixis, Inc.
(Exact name of registrant as specified in its charter)

----------------

  Delaware                     8731                   04-3257395
 (State or other           (Primary Standard          (I.R.S. Employer
  jurisdiction of       Industrial Classification    Identification No.)
incorporation or             Code Number)                           
organization)                                                     

----------------

260 Littlefield Avenue
South San Francisco, CA 94080 
(650) 825-2200
(Address, including zip code, and telephone number, including area code, of 
registrant's principal executive offices) 

----------------

GEORGE A. SCANGOS 
President and Chief Executive Officer 
260 Littlefield Avenue
South San Francisco, CA 94080 
(650) 825-2200
(Name, address, including zip code, and telephone number, including area code,
of agent for service) 

----------------

Copies to:
ROBERT L. JONES, ESQ. DEBORAH A.     ALISON S. RESSLER, ESQ. Sullivan &   
MARSHALL, ESQ. Cooley Godward LLP   Cromwell 1888 Century Park East Suite   
Five Palo Alto Square 3000 El Camino 2100 Los Angeles, CA 90067-1725 (310)    
Real Palo Alto, CA 94306-2155 (650)                 712-6600                  
843-5000                                          

----------------

Approximate date of proposed sale to the public: As soon as practicable   
after the effective date of this registration statement as the underwriters     
shall determine.                                                                
 If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of  
1933, as amended (the "Securities Act"), check the following box. [_]           
If this Form is filed to register additional securities for an offering   
pursuant to Rule 462(b) under the Securities Act, check the following box and   
list the Securities Act registration statement number of the earlier effective  
registration statement for the same offering. [_]                               
If this Form is a post-effective amendment filed pursuant to Rule 462(c)  
under the Securities Act, check the following box and list the Securities Act   
registration statement number of the earlier effective registration statement   
number for the same offering. [_]                                               

If this Form is a post-effective amendment filed pursuant to Rule 462(d)  
under the Securities Act, check the following box and list the Securities Act   
registration number of the earlier effective registration statement for the     
same offering. [X]                                                              
If delivery of the prospectus is expected to be made pursuant to Rule 434,
check the following box. [_]                                                    

----------------

The registrant hereby amends this Registration Statement on such date or  
dates as may be necessary to delay its effective date until the registrant      
shall file a further amendment which specifically states that this Registration 
Statement shall thereafter become effective in accordance with Section 8(a) of  
the Securities Act of 1933, as amended, or until the Registration Statement     
shall become effective on such date as the Commission, acting pursuant to said  
Section 8(a), may determine.                                                    

--------------------------------------------------------------------------------
--------------------------------------------------------------------------------

POS EX 2nd Page of 10 TOC 1st Previous Next ↓Bottom Just 2nd
EXPLANATORY NOTE

This Post-effective Amendment No. 1 to Registration Statement on Form S-1 
(File No. 333-96335) is an exhibit-only filing to refile exhibit 10.13 to the   
Registration Statement to correct an error.                                     

1 

POS EX 3rd Page of 10 TOC 1st Previous Next ↓Bottom Just 3rd
PART II 

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution                            

The following table sets forth the costs and expenses, other than the     
underwriting discounts payable by us, in connection with the sale of common     
stock being registered. All amounts are estimates except the SEC registration   
fee, the NASDAQ filing fee and the Nasdaq National Market listing fee.          

                                                                [Download Table]
                                                                            
SEC registration fee............................................. $   30,391
NASDAQ filing fee................................................     10,500
Nasdaq National Market listing fee...............................     95,000
Blue Sky Fees and expenses.......................................      5,000
Transfer Agent and registrar fees................................     10,000
Accounting fees and expenses.....................................    350,000
Legal fees and expenses..........................................    500,000
Printing and engraving costs.....................................    345,000
Miscellaneous expenses...........................................     54,109
                                                                  ----------
  Total.......................................................... $1,400,000
                                                                  ==========

Item 14. Indemnification of Directors and Officers                              

As permitted by Delaware law, our amended and restated certificate of     
incorporation provides that no director of ours will be personally liable to us 
or our stockholders for monetary damages for breach of fiduciary duty as a      
director, except for liability:                                                 

. for any breach of duty of loyalty to us or to our stockholders;           

. for acts or omissions not in good faith or that involve intentional       
misconduct or a knowing violation of law;                               

. for unlawful payment of dividends or unlawful stock repurchases or        
 redemptions under Section 174 of the Delaware General Corporation Law; or

. for any transaction from which the director derived an improper personal  
benefit.                                                                

 Our amended and restated certificate of incorporation further provides that
we must indemnify our directors and executive officers and may indemnify our    
other officers and employees and agents to the fullest extent permitted by      
Delaware law. We believe that indemnification under our amended and restated    
certificate of incorporation covers negligence and gross negligence on the part 
of indemnified parties.                                                         

We have entered into indemnification agreements with each of our directors
and certain officers. These agreements, among other things, require us to       
indemnify each director and officer for certain expenses including attorneys'   
fees, judgments, fines and settlement amounts incurred by any such person in    
any action or proceeding, including any action by or in the right of Exelixis,  
Inc., arising out of the person's services as our director or officer, any      
subsidiary of ours or any other company or enterprise to which the person       
provides services at our request.                                               

The underwriting agreement (see Exhibit 1.1) will provide for             
indemnification by the underwriters of Exelixis, Inc., our directors, our       
officers who sign the registration statement, and our controlling persons for   
some liabilities, including liabilities arising under the Securities Act.       

II-1

POS EX 4th Page of 10 TOC 1st Previous Next ↓Bottom Just 4th
Item 15. Recent Sales of Unregistered Securities                                

Since January 1, 1997, Exelixis, Inc. has sold and issued the following   
unregistered securities:                                                        

(1) From January 1997 through March 2000, Exelixis has granted stock  
options to purchase 8,341,130 shares of common stock, at a weighted average 
exercise price of $0.79, to employees, consultants and directors. Of these  
stock options, 724,790 shares have been cancelled or have lapsed without    
being exercised, 6,551,814 shares have been exercised for common stock and  
1,064,526 shares remain outstanding.                                        

(2) In April 1997, Exelixis issued an aggregate of 7,875,000 shares of
Series C preferred stock to 41 accredited investors at $2.00 per share, for 
an aggregate purchase price of $15,750,000. Shares of Series C preferred    
stock are convertible into shares of common stock at the rate of 0.75 of a  
share of common stock for each share of Series C preferred stock            
outstanding.                                                                

(3) In September 1997, Exelixis issued one warrant to purchase 63,750 
shares of common stock to one purchaser at an exercise price of $2.67 per   
share.                                                                      

(4) From August 1998 to June 1999, Exelixis issued an aggregate of    
2,500,000 shares of Series D preferred stock to 11 accredited investors at  
$3.00 per share, for an aggregate purchase price of $7.5 million. In this   
period, Exelixis issued an additional 2,500,000 shares of Series D          
preferred stock to Pharmacia & Upjohn, Inc. at $3.00 per share, for an      
aggregate purchase price of $7.5 million pursuant to the terms of a         
development agreement dated February 26, 1999. Shares of Series D preferred 
stock are convertible at the rate of 0.75 of a share of common stock for    
each share of Series D preferred stock outstanding.                         

(5) In November 1999 Exelixis issued three warrants to purchase an    
aggregate of 112,500 shares of common stock to three purchasers at an       
exercise price of $4.00 per share.                                          

Item 16. (A) Exhibits and Financial Statement Schedules                         

                                                                [Download Table]
                                                                          
1.1+ Form of Underwriting Agreement.                                      
3.1+ Restated Certificate of Incorporation of Registrant, dated January   
     25, 1999.                                                            
3.2+ Certificate of Amendment of the Restated Certificate of Incorporation
     of Registrant, dated February 2, 2000.                               
3.3+ Certificate of Amendment of the Amended and Restated Certificate of  
     Incorporation of Registrant, dated April 5, 2000.                    
3.4+ Form of Restated Certificate of Incorporation of Registrant to be    
     filed upon the closing of the offering made in connection with this  
     Registration Statement.                                              
3.5+ Amended and Restated Bylaws of Registrant to be filed upon the       
     closing of the offering made in connection with this Registration    
     Statement.                                                           
4.1+ Specimen Common Stock Certificate.                                   
4.2+ Fourth Amended and Restated Registration Rights Agreement, dated     
     February 26, 1999 among Registrant and Certain Stockholders of       
     Registrant.                                                          
4.3+ Warrant, dated August 17, 1998, to Purchase 167,728 shares of Series 
     A Preferred Stock in favor of Comdisco, Inc. (125,796 post-split     
     shares).                                                             
4.4+ Warrant, dated August 17, 1998, to Purchase 20,486 shares of Series A
     Preferred Stock in favor of Greg Stento (15,365 post-split shares).  
4.5+ Warrant, dated January 24, 1996, to Purchase 357,143 shares of Series
     B Convertible Stock in favor of MMC/GATX Partnership No. 1 (267,857  
     post-split shares).                                                  

II-2

POS EX 5th Page of 10 TOC 1st Previous Next ↓Bottom Just 5th
                                                                [Download Table]
                                                                          
 4.6+   Warrant, dated September 25, 1997, to Purchase 85,000 shares of   
        Common Stock in favor of MMC/GATX Partnership No. 1 (63,750 post- 
        split shares).                                                    
 4.7+   Warrant, dated November 15, 1999, to Purchase 12,000 shares of    
        Common Stock in favor of Bristow Investments, L.P. (9,000 post-   
        split shares).                                                    
 4.8+   Warrant, dated November 15,1999, to Purchase 135,000 shares of    
        Common Stock in favor of Slough Estates USA, Inc. (101,250 post-  
        split shares).                                                    
 4.9+   Warrant, dated November 15, 1999, to Purchase 3,000 shares of     
        Common Stock in favor of Laurence and Magdalena Shushan           
        FamilyTrust (2,250 post-split shares).                            
 5.1+   Opinion of Cooley Godward LLP.                                    
10.1+   Form of Indemnity Agreement.                                      
10.2+   1994 Employee, Director and Consultant Stock Plan.                
10.3+   1997 Equity Incentive Plan.                                       
10.4+   2000 Equity Incentive Plan.                                       
10.5+   2000 Non-Employee Directors' Stock Option Plan.                   
10.6+   2000 Employee Stock Purchase Plan.                                
10.7++  Collaboration Agreement, dated December 16, 1999, between         
        Registrant, Bayer Corporation and GenOptera LLC.                  
10.8++  Operating Agreement, dated December 15, 1999, between Registrant, 
        Bayer Corporation and GenOptera LLC.                              
10.9+   Cooperation Agreement, dated September 15, 1998, between          
        Registrant and Artemis Pharmaceuticals, GmbH.                     
10.10+  Sublease Agreement, dated June 1, 1997, between Arris             
        Pharmaceutical Corporation and Registrant.                        
10.11+  Lease, dated May 12, 1999, between Registrant and Britannia Pointe
        Grand Limited Partnership.                                        
10.12+  Master Services Agreement, dated November 15, 1999, between       
        Registrant and Artemis Pharmaceuticals GmbH.                      
10.13+* Research Collaboration and Technological Transfer Agreement, dated
        September 14, 1999, between Registrant and Bristol-Myers Squibb.  
10.14++ Corporate Collaboration Agreement, dated February 26, 1999,       
        between Registrant and Pharmacia & Upjohn AB.                     
10.15++ Amendment to Corporate Collaboration Agreement, dated October,    
        1999, between Registrant and Pharmacia & Upjohn AB.               
10.16+  Asset Purchase Agreement, dated July 11, 1999, between Registrant 
        and MetaXen/Xenova.                                               
10.17+  Employment Agreement, dated September 13, 1996, between Registrant
        and George Scangos, Ph.D.                                         
10.18+  Employment Agreement, dated April 14, 1997, between Registrant and
        Geoffrey Duyk, M.D., Ph.D.                                        
10.19+  Employment Agreement, dated October 19, 1999, between Registrant  
        and Glen Y. Sato, Chief Financial Officer and Vice President of   
        Legal Affairs.                                                    
23.1+   Consent of Independent Accountants (Exelixis).                    
23.2+   Consent of Independent Accountants (MetaXen).                     
23.3+   Consent of Cooley Godward LLP (included in Exhibit 5.1).          

II-3

POS EX 6th Page of 10 TOC 1st Previous Next ↓Bottom Just 6th
                                                                [Download Table]
                                                      
24.1+ Power of Attorney (contained on signature page).
27.1+ Financial Data Schedule.                        

--------                                                                        
+  Previously filed.                                                          
*  Filed herewith.                                                            
+ Confidential treatment requested for certain portions of this exhibit.      

(b) Financial Statement Schedules                                         

All schedules for which provision is made in the applicable accounting    
regulations of the Securities and Exchange Commission are not required under    
the related instructions or are inapplicable, and therefore have been omitted.  

Item 17. Undertakings                                                           

The registrant hereby undertakes to provide to the Underwriters at the    
closing specified in the Underwriting Agreement certificates in such            
denominations and registered in such names as required by the Underwriters to   
permit prompt delivery to each purchaser.                                       

 Insofar as indemnification for liabilities arising under the Securities Act
of 1933 may be permitted to directors, officers and controlling persons of the  
registrant pursuant to the foregoing provisions, or otherwise, the registrant   
has been advised that in the opinion of the Securities and Exchange Commission  
such indemnification is against public policy as expressed in the Act, and is,  
therefore, unenforceable. In the event that a claim for indemnification against 
such liabilities (other than the payment by the registrant of expenses incurred 
or paid by a director, officer, or controlling person of the registrant in the  
successful defense of any action, suit or proceeding) is asserted by such       
director, officer or controlling person in connection with the securities being 
registered, the registrant will, unless in the opinion of its counsel the       
matter has been settled by controlling precedent, submit to a court of          
appropriate jurisdiction the question whether such indemnification by it is     
against public policy as expressed in the Act and will be governed by the final 
adjudication of such issue.                                                     

The undersigned registrant hereby undertakes that:                        

(1) For purposes of determining any liability under the Securities Act
of 1933, the information omitted from the form of prospectus filed as part  
of this Registration Statement in reliance upon Rule 430A and contained in  
a form of Prospectus filed by the registrant pursuant to Rule 424(b)(1) or  
(4) or 497(h) under the Securities Act shall be deemed to be part of this   
Registration Statement as of the time it was declared effective.            

(2) For the purpose of determining any liability under the Securities 
Act of 1933, each post-effective amendment that contains a form of          
prospectus shall be deemed to be a new registration statement relating to   
the securities offered therein, and the offering of such securities at that 
time shall be deemed to be the initial bona fide offering thereof.          

II-4

POS EX 7th Page of 10 TOC 1st Previous Next ↓Bottom Just 7th
SIGNATURES

 Pursuant to the requirements of the Securities Act of 1933, as amended,
the Registrant has caused this Post-effective Amendment No. 1 to Registration   
Statement to be signed on its behalf by the undersigned, thereunto duly         
authorized, in the County of South San Francisco, State of California on the    
10th day of April, 2000.                                                        

                  Exelixis, Inc.

                                         /s/ George A. Scangos, Ph.D
                                         By: _________________________________
                                           George A. Scangos, Ph.D
                                           President and Chief Executive
                                           Officer

  Pursuant to the requirements of the Securities Act of 1933, as amended, this
Post-effective Amendment No. 1 to Registration Statement has been signed below  
by the following persons in the capacities and on the dates indicated.          

                                                                [Download Table]

              Signature                          Title                 Date     
              ---------                          -----                 ----     

                                                                                
    /s/ George A. Scangos, Ph.D.       President, Chief Executive April 10, 2000
______________________________________  Officer and Director                    
       George A. Scangos, Ph.D.         (principal executive                    
                                        officer)                                

          /s/ Glen Y. Sato             Chief Financial Officer    April 10, 2000
______________________________________  (principal financial and                
             Glen Y. Sato               accounting officer)                     

                  *                    Chairman of the Board of   April 10, 2000
______________________________________  Directors                               
     Stelios Papadopoulos, Ph.D.                                                

                  *                    Director                   April 10, 2000
______________________________________                                          
         Charles Cohen, Ph.D.                                                   

                  *                    Director                   April 10, 2000
______________________________________                                          
          Jurgen Drews, M.D.                                                    

                  *                    Director                   April 10, 2000
______________________________________                                          
      Geoffrey Duyk, M.D., Ph.D.                                                

                  *                    Director                   April 10, 2000
______________________________________                                          
       Jason S. Fisherman, M.D.                                                 

                  *                    Director                   April 10, 2000
______________________________________                                          
     Jean-Francois Formela, M.D.                                                

II-5

POS EX 8th Page of 10 TOC 1st Previous Next ↓Bottom Just 8th
                                                                [Download Table]

              Signature                          Title                 Date     
              ---------                          -----                 ----     

                                                                                
                  *                    Director                   April 10, 2000
______________________________________                                          
            Edmund Olivier                                                      

                  *                    Director                   April 10, 2000
______________________________________                                          
         Lance Willsey, M. D.                                                   

                  *                    Director                   April 10, 2000
______________________________________                                          
         Peter Stadler, Ph.D.                                                   

                                                                [Download Table]
                                          
          /s/ Glen Y. Sato                
*By: _________________________________    
           Attorney-in-fact               

II-6

POS EX 9th Page of 10 TOC 1st Previous Next ↓Bottom Just 9th
Exhibit Index 

                                                                [Download Table]

Exhibit                                                                       
Number                                Description                             
-------                               -----------                             
                                                                              
 1.1+   Form of Underwriting Agreement.                                       
 3.1+   Restated Certificate of Incorporation of Registrant, dated January 25,
        1999.                                                                 
 3.2+   Certificate of Amendment of the Restated Certificate of Incorporation 
        of Registrant, dated February 2, 2000.                                
 3.3+   Certificate of Amendment of the Amended and Restated Certificate of   
        Incorporation of Registrant, dated April 5, 2000.                     
 3.4+   Form of Restated Certificate of Incorporation of Registrant to be     
        filed upon the closing of the offering made in connection with this   
        Registration Statement.                                               
 3.5+   Amended and Restated Bylaws of Registrant to be filed upon the closing
        of the offering made in connection with this Registration Statement.  
 4.1+   Specimen Common Stock Certificate.                                    
 4.2+   Fourth Amended and Restated Registration Rights Agreement, dated      
        February 26, 1999 among Registrant and Certain Stockholders of        
        Registrant.                                                           
 4.3+   Warrant, dated August 17, 1998, to Purchase 167,728 shares of Series A
        Preferred Stock in favor of Comdisco, Inc. (125,796 post-split        
        shares).                                                              
 4.4+   Warrant, dated August 17, 1998, to Purchase 20,486 shares of Series A 
        Preferred Stock in favor of Greg Stento (15,365 post-split shares).   
 4.5+   Warrant, dated January 24, 1996, to Purchase 357,143 shares of Series 
        B Convertible Stock in favor of MMC/GATX Partnership No. 1 (267,857   
        post-split shares).                                                   
 4.6+   Warrant, dated September 25, 1997, to Purchase 85,000 shares of Common
        Stock in favor of MMC/GATX Partnership No. 1 (63,750 post-split       
        shares).                                                              
 4.7+   Warrant, dated November 15, 1999, to Purchase 12,000 shares of Common 
        Stock in favor of Bristow Investments, L.P. (9,000 post-split shares).
 4.8+   Warrant, dated November 15, 1999, to Purchase 135,000 shares of Common
        Stock in favor of Slough Estates USA, Inc. (101,250 post-split        
        shares).                                                              
 4.9+   Warrant, dated November 15, 1999, to Purchase 3,000 shares of Common  
        Stock in favor of Laurence and Magdalena Shushan FamilyTrust (2,250   
        post-split shares).                                                   
 5.1+   Opinion of Cooley Godward LLP.                                        
10.1+   Form of Indemnity Agreement.                                          
10.2+   1994 Employee, Director and Consultant Stock Plan.                    
10.3+   1997 Equity Incentive Plan.                                           
10.4+   2000 Equity Incentive Plan.                                           
10.5+   2000 Non-Employee Directors' Stock Option Plan.                       
10.6+   2000 Employee Stock Purchase Plan.                                    
10.7++  Collaboration Agreement, dated December 16, 1999, between Registrant, 
        Bayer Corporation and GenOptera LLC.                                  
10.8++  Operating Agreement, dated December 15, 1999, between Registrant,     
        Bayer Corporation and GenOptera LLC.                                  
10.9+   Cooperation Agreement, dated September 15, 1998, between Registrant   
        and Artemis Pharmaceuticals GmbH.                                     

POS EX Last Page of 10 TOC 1st Previous Next ↓Bottom Just 10th
                                                                [Download Table]
                                                                              
10.10+  Sublease Agreement, dated June 1, 1997, between Arris Pharmaceutical  
        Corporation and Registrant.                                           
10.11+  Lease, dated May 12, 1999, between Registrant and Britannia Pointe    
        Grand Limited Partnership.                                            
10.12+  Master Services Agreement, dated November 15, 1999, between Registrant
        and Artemis Pharmaceuticals GmbH.                                     
10.13+* Research Collaboration and Technological Transfer Agreement, dated    
        September 14, 1999, between Registrant and Bristol-Myers Squibb.      
10.14++ Corporate Collaboration Agreement, dated February 26, 1999, between   
        Registrant and Pharmacia & Upjohn AB.                                 
10.15++ Amendment to Corporate Collaboration Agreement, dated October, 1999,  
        between Registrant and Pharmacia & Upjohn AB.                         
10.16+  Asset Purchase Agreement, dated July 11, 1999, between Registrant and 
        MetaXen/Xenova.                                                       
10.17+  Employment Agreement, dated September 13, 1996, between Registrant and
        George Scangos, Ph.D.                                                 
10.18+  Employment Agreement, dated April 14, 1997, between Registrant and    
        Geoffrey Duyk, M.D., Ph.D.                                            
10.19+  Employment Agreement, dated October 19, 1999, between Registrant and  
        Glen Y. Sato, Chief Financial Officer and Vice President of Legal     
        Affairs.                                                              
23.1+   Consent of Independent Accountants (Exelixis).                        
23.2+   Consent of Independent Accountants (MetaXen).                         
23.3+   Consent of Cooley Godward LLP (included in Exhibit 5.1).              
24.1+   Power of Attorney (contained on signature page).                      
27.1+   Financial Data Schedule.                                              

--------                                                                        
+  Previously filed.                                                          
*  Filed herewith.                                                            
+ Confidential treatment requested for certain portions of this exhibit.

POS EX	1st Page of 10	TOC	↑Top	Previous	Next	↓Bottom	Just 1st

POS EX	2nd Page of 10	TOC	1st	Previous	Next	↓Bottom	Just 2nd

POS EX	3rd Page of 10	TOC	1st	Previous	Next	↓Bottom	Just 3rd

POS EX	4th Page of 10	TOC	1st	Previous	Next	↓Bottom	Just 4th

POS EX	5th Page of 10	TOC	1st	Previous	Next	↓Bottom	Just 5th

POS EX	6th Page of 10	TOC	1st	Previous	Next	↓Bottom	Just 6th

POS EX	7th Page of 10	TOC	1st	Previous	Next	↓Bottom	Just 7th

POS EX	8th Page of 10	TOC	1st	Previous	Next	↓Bottom	Just 8th

POS EX	9th Page of 10	TOC	1st	Previous	Next	↓Bottom	Just 9th

POS EX	Last Page of 10	TOC	1st	Previous	Next	↓Bottom	Just 10th

Dates Referenced Herein and Documents Incorporated by Reference

		Referenced-On Page
This ‘POS EX’ Filing	Date	First	Last	Other Filings

Filed on / Effective on:	4/11/00			424B4
	4/10/00	1	8
	4/5/00	4	9
	2/2/00	4	9
	12/16/99	5	9
	12/15/99	5	9
	11/15/99	5	10
	10/19/99	5	10
	9/14/99	5	10
	7/11/99	5	10
	5/12/99	5	10
	2/26/99	4	10
	1/25/99	4	9
	9/15/98	5	9
	8/17/98	4	9
	9/25/97	5	9
	6/1/97	5	10
	4/14/97	5	10
	1/1/97	4
	9/13/96	5	10
	1/24/96	4	9
				List all Filings

↑Top

Filing Submission 0001012870-00-002020 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Exelixis, Inc. – IPO: ‘POS EX’ on 4/11/00

On: Tuesday, 4/11/00 · Effective: 4/11/00 · Accession #: 1012870-0-2020 · File #: 333-96335

Initial Public Offering (IPO): Post-Effective Amendment to Add ExhibitsFiling Table of Contents

POS EX — Post Effective Amendment #1Document Table of Contents

Dates Referenced Herein and Documents Incorporated by Reference

Initial Public Offering (IPO): Post-Effective Amendment to Add Exhibits
Filing Table of Contents

POS EX — Post Effective Amendment #1
Document Table of Contents